Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Swedbank Mortgage AB Interim report January – June 2017

Please access the complete report at www.swedbank.com/ir or in the enclosed pdf.Swedbank Mortgage AB (in Swedish: Swedbank Hypotek) is a wholly owned subsidiary to Swedbank AB (publ). The mortgage lending is mainly originated through Swedbank’s and the savings banks retail network as well as the Telephone bank, one of the largest bank-owned distribution networks in Sweden. No lending is performed outside of Sweden. Swedbank Mortgage AB (publ) is required to disclose this information pursuant to Regulation (EU) No 596/2014 on market abuse, the Swedish Securities Market Act (2007:528) and/

OV to evaluate the potential of in-licensing a small molecule compound for development in cancer from a major Pharmaceutical company

Hoersholm, Denmark, July 19th, 2017 – Oncology Venture AB (OV:ST) and Novartis Pharma AG (Basel, Switzerland) have entered into an agreement providing Oncology Venture with an option right to  execute an exclusive license to develop and commercialize an undisclosed small molecule, kinase inhibitor in clinical development. The molecule has been explored in multiple therapeutic indications including a variety of solid tumors.  Further terms of the agreement were not disclosed.Under the option agreement, OV will evaluate whether it can suitably develop and validate a companion diagnostic for

Disclosure notice: NextCell Pharma AB’s Chairman of the Board acquires additional shares

NextCell Pharma AB (”NextCell”) announces today, on July 19th 2017, that Chairman of the Board, Anders Essen-Möller, has acquired 263.020 shares in the company. Before the acquisition, Essen-Möller held 737.033 shares, equivalent to approximately 8.74 percent of the votes and capital. After the acquisition, Essen-Möller holds 1.000.053 shares, equivalent to approximately 11.76 percent of the votes and capital in NextCell.

Another preclinical paper on the Episealer implant published

Another preclinical paper has been published that again validates Episurf Medical’s (NASDAQ: EPIS B) patented cartilage repair technology to treat knee pain. The study titled “Cartilage Health in Knees Treated with Metal Resurfacing Implants or Untreated Focal Cartilage Lesions: A Preclinical Study in Sheep” by N. Martinez-Carranza et al. is now available online in the medical journal “Cartilage”. Whilst the paper looks at the positive impact of the Episealer knee implant, it also indicates that the biological coatings applied to the implant maintain the health of the surrounding cartilage,

CELLINK publishes quarterly report for the third quarter

CELLINK AB ("CELLINK" or "Company") publishes quarterly report for the period 1st of March 2017 – 31th of May 2017 and the results for the first nine months. The report is available on the company's website: http://cellink.com/investor-relations/. This press release presents a summary of the report. Quarter 3 (Q3), March 1st, 2016 - May 31st, 2017 ·        Operating revenues amounted to 5,162 kSEK ·        Net sales of 3,103 kSEK ·        Operating profit before depreciation, EBITDA amounted to -441 kSEK ·        Operating profit amounted to -537 kSEK ·        Profit

Interim Report January-June 2017

Highlights during the second quarter · Adjusted net asset value*, based on estimated market values for the major wholly-owned subsidiaries and partner-owned investments within Patricia Industries, amounted to SEK 376,736 m. (SEK 493 per share) on June 30, 2017. Adjusted for the dividend paid, adjusted net asset value increased by SEK 12,600 m., or 3 percent, during the quarter. · Reported net asset value1)* amounted to SEK 331,238 m. (SEK 433 per share) on June 30, 2017, an increase of SEK 1,041 m. (SEK 1 per share) during the quarter. Adjusted for the dividend paid, reported net

Interim report January–June 2017

Gothenburg, Sweden – Collector AB (publ) (Nasdaq Stockholm: COLL)JANUARY – JUNE 2017 (COMPARED WITH JANUARY–JUNE 2016) · Total income increased by 29%, amounting to SEK 911 million (708) · Earnings after tax (EAT) increased by 35%, amounting to SEK 241 million (179) · Return on equity (RoE) was 19% (21) · Earnings per share increased to SEK 2.35 (1.82) · Continued strong growth with increased quality in the credit portfolio, SEK 17,090 million (10,865) +57% · Positive development in credit losses 1.1% (1.2) · Communication from Collector´s Annual General Meeting of 25

The board of directors exercises authorization for repurchase of shares to secure the company’s commitments under incentive programme

The annual general meeting of Swedish Orphan Biovitrum AB (publ)  on 4 May 2017 resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the annual general meeting – on a directed share issue of no more than 496,760 redeemable- and convertible class C shares. The general meeting also resolved to authorize the board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorization may be made on

Gunnebo Interim Report January-June 2017

CEO’S COMMENTS ON THE SECOND QUARTER 2017 The second quarter was in line with the same period last year with a turnover of MSEK 1,510 and an operating margin of 6.8% excluding non-recurring items. Growth has been good within both Entrance Security and Cash Management. DEVELOPMENT OF OUR BUSINESSIn region EMEA sales developed well during the second quarter in all sub-regions with the exception of France and South Africa. It is positive that the operating margin in EMEA for the quarter is on the same level as last year, despite organic sales growth of -2%. Excluding France, organic

Electrolux President and CEO Jonas Samuelson’s comments on the results for the second quarter 2017

Significant earnings improvement across the GroupDuring the second quarter Electrolux improved its operating income by close to 25%, achieving an operating margin of 6.2%. Profitability increased in most of our business areas. This was driven by continued focus on improving product mix through active portfolio management, and increased cost efficiency within our operations. Cash flow continued to be strong, further strengthening our balance sheet. In EMEA, our premium brands continued to gain market share driven by the built-in kitchen segment. The launch of the new AEG products is

Nordnet Interim Report January–June 2017

April–June 2017 · Operating income increased by 1 percent to SEK 296.9 million (293.5) · Operating profit decreased by 50 percent to 43.0 million (86.8) · Profit after tax for the period fell by 46 percent to SEK 37.3 million (68.5) · The building of the new Nordnet has begun, extraordinary costs during the second quarter amount to SEK 31.6 million January–June 2017 · Operating income increased by 5 percent to SEK 620.7 million (592.4) · Operating profit decreased by 19 percent to 142.7 million (176.0) · Profit after tax for the period fell by 16 percent to SEK

INTERIM REPORT 1 JANUARY – 30 JUNE 2017

Second quarter (1 April – 30 June 2017)  · Net sales for the quarter amounted to MSEK 111 (90). · Operating profit before depreciation and amortisation (EBITDA) was MSEK 51 (17), of which associates had an impact of MSEK 0 (0) on the Group. Operating cash flow was MSEK -34 (-7). · Profit/loss before tax amounted to MSEK 9 (-34). · Profit/loss after tax amounted to MSEK 8 (-27), or SEK 0.24 (-0.81) per share. · Production totalled 141 GWh (116), of which Own wind power operations accounted for 85 GWh (68) and Co-owned wind power operations for 56 GWh (48). The increase was

REPORT FOR THE SECOND QUARTER 2017 AND THE FIRST HALF YEAR 2017

Financial and operating highlights 2Q 2017 (2Q 2016 in brackets): · Operating revenues were NOK 2 036 million (NOK 3 151 million)  · EBITDA  was NOK 695 million (NOK 1 379 million) · Year on year EBITDA improvement of NOK 254 million, apart from Offshore drilling ·  EBIT (operating result) was NOK - 652 million (NOK -824 million) ·  Net finance was NOK - 61 million (NOK - 9 million).            ·  Net result after tax was NOK -812 million (NOK -1 012 million) Offshore drilling · EBITDA NOK 240 mill. (NOK 1 178 mill.) · Impairment on offshore units

Interim report Rejlers AB January - June 2017

Norwegian business puts pressure on profitabilitySecond quarter• Sales increased by 2 % to SEK 623.0 million (608.2)• Organic sales growth excluding exchange rate fluctuations was 0 %• EBITA (adjusted) amounted to SEK 1.7 million (29.2) and the adjusted EBITA margin amounted to 0.3 % (4.8)• Operating profit/loss amounted to SEK -14.4 million (22.6) and the operating margin was -2.3 % (3.7).• Profit/loss after tax was SEK -10.5 million (18.4)• Earnings per share before and after dilution were SEK -0.89 (-1.39)• Cash flow from operating activities totalled SEK -16.0 million (10.

Electrolux Interim Report January - June 2017

Highlights of the second quarter of 2017· Net sales increased by 5.1% to SEK 31,502m (29,983).                       · Organic sales were unchanged, contribution from acquisitions and divestments was 1.2% while currency translation had a positive impact of 3.9% on net sales. · Operating income increased to SEK 1,942m (1,564), corresponding to a margin of 6.2% (5.2). · Four of six business areas achieved an operating margin above 6%. · Solid operating cash flow after investments of SEK 3.5bn (4.1). · Income for the period increased to SEK 1,308m (1,079), and earnings per share

Lagercrantz Interim Report 2017/18 Q1

1 April – 30 June 2017 · Net revenue amounted to MSEK 794 (781). · Operating profit (EBITA) amounted to MSEK 100 (96), equivalent to an operating margin of 12.6 percent (12.3). · Profit before financial items amounted to MSEK 87 (83), equivalent to an EBIT margin of 11.0 percent (10.6). · Profit after financial items amounted to MSEK 82 (82). · Profit after taxes amounted to MSEK 65 (64). · Earnings per share after dilution amounted to SEK 0.95 (0.94) for the quarter and for the moving 12-month period to SEK 4.06, compared to SEK 4.02 for the 2016/17 financial year. ·

Interim Report January – June 2017

– Growth in the building rights portfolio, continued strategic cooperation, successful conversion projects and an agreement to purchase Svenska Vårdfastigheter AB create conditions for increased profitability.Interim Period April–June 2017 · •       Net sales increased to SEK 790 million (434). · •       The company reported an operating profit of SEK 126 million (116). · •       Net profit for the period amounted to SEK 101 million (86). Earnings per share, after deductions for minority shares, amounted to SEK 1.64/share (1.72). · •       During the period, Magnolia Bostad

Another good quarter for ASSA ABLOY

Second quarter · Net sales increased by 8% to SEK 19,387 M (17,894), with organic growth of 2% (4) and acquired growth of 2% (4) · Good growth was shown by EMEA, Americas, Global Technologies and Entrance Systems and negative growth by Asia Pacific · Contracts have been signed for the acquisition of five companies with expected combined annual sales of about SEK 900 M · Operating income (EBIT) increased by 7% to SEK 3,114 M (2,910). The operating margin was 16.1% (16.3) · Net income amounted to SEK 2,179 M (2,026) · Earnings per share increased by 8% and amounted to SEK

Q2 2017: Probi completes integration and ends first half of 2017 with increase in sales and earnings

Highlights and significant events during the second quarter • Robust growth in sales and earnings despite inventory management at one of the largest customers• Successful completion of integration process, strengthening of marketing and sales organization and finalization of purchase price allocation at Probi USA• Several new distribution agreements in EMEA• Launch of research program targeted at next generation probiotics and prebiotics Financial overview MSEK H1 2017 H1 2016 Full -year

SBAB Interim Report January–June 2017

SBAB’s Interim Report January–June 2017 is now available for download on www.sbab.se/IR. Q2 2017 (Q1 2017) ·  Total lending: SEK 315.6 billion (305.1) ·  Total deposits: SEK 102.7 billion (100.0) ·  Operating profit: SEK 539 million (549) ·  Net interest income: SEK 777 million (779) ·  Expenses: SEK 244 million (232) ·  C/I ratio: 31.2 % (29.9) ·  Net loan losses: SEK 1 million (recovery: 6) ·  Return on equity: 12.4% (12.6) ·  Common Equity Tier 1 (CET1) capital ratio:

The Swedish Covered Bond Corporation (SCBC) Interim Report January–June 2017

The Swedish Covered Bond Corporation (SCBC) Interim Report January–June 2017 has been published on www.sbab.se/ir. January–June 2017 (January– June 2016) · Operating profit: SEK 1,023 million (842) · Net interest income: SEK 1,432 million (1,262) · Expenses: SEK 375 million (344) · Net loan losses: recovery of SEK 10 million (recovery: 1) · The Common Equity Tier 1 (CET1) capital ratio: 88.3% (72.6) · All funding programmes continue to have the highest credit ratings from Moody’s

Strong second quarter result for Södra

Södra´s operating profit totalled SEK 464 million (50) for the second quarter. The trend was boosted by favourable demand for Södra’s products, higher prices and internal operational improvements."The overall forest economy remains strong, which is to Södra’s advantage. Higher prices for both market pulp and sawn timber contributed to a strong quarter for Södra. A firmer customer and market orientation is also yielding results. In addition, the expansion investments at our pulp mills and the restructuring process in the sawmill operations had a positive impact on operating profit", said

Sobi™ publishes its report for the second quarter 2017

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the second quarter 2017. Total revenues amounted to SEK 1,639 M, an increase of 12 per cent. Total revenue growth was 51 per cent excluding one-time items. Product sales amounted to SEK 1,443 M, an increase of 12 per cent (60 per cent adjusted). Elocta® sales were SEK 351 M and Alprolix® sales were SEK 84 M. Business highlights Q2 2017 · Guido Oelkers was appointed CEO and President · Strong quarter on quarter growth · A new Specialty Care business unit was established · Elocta

There are no items matching the current filter
There are no more items matching the current filter
Back to top